Mulpleta Tablet, Film Coated
NDC Package 85320-551-07
Package Information
Mulpleta (lusutrombopag) tablets is a medication used by people with chronic liver disease and a certain blood disorder (low platelet count) who are scheduled to have a medical or dental procedure. This formulation utilizes a tablet, film coated delivery system. Marketed by Eddingpharm (u. S. ) Inc., this product is identified by NDC 85320-551 and is authorized under FDA application NDA210923.
Identification & Billing
- RxCUI: 2054989 - lusutrombopag 3 MG Oral Tablet
- RxCUI: 2054995 - MULPLETA 3 MG Oral Tablet
- RxCUI: 2054995 - lusutrombopag 3 MG Oral Tablet [Mulpleta]
- RxCUI: 2054995 - Mulpleta 3 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 85320 - Eddingpharm (u. S. ) Inc.
- 85320-551 - Mulpleta
- 85320-551-07 - 1 DOSE PACK in 1 CARTON / 7 TABLET, FILM COATED in 1 DOSE PACK
- 85320-551 - Mulpleta
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 85320-551-07 identifies a specific commercial package of 1 dose pack in 1 carton / 7 tablet, film coated in 1 dose pack of Mulpleta, a human prescription drug labeled by Eddingpharm (u. S. ) Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet, film coated is formulated for oral use and contains lusutrombopag as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eddingpharm (u. S. ) Inc. on November 24, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used by people with chronic liver disease and a certain blood disorder (low platelet count) who are scheduled to have a medical or dental procedure. Having a low platelet count increases the risk of too much bleeding during certain procedures. This medication increases the production of platelets by your body to help prevent too much bleeding from the procedure.
How is this Eddingpharm (u. S. ) Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 85320055107. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.